Article Text

Download PDFPDF
Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor Josef S Smolen

  • Twitter @FragoulisGeorge, @Dr_C_Koutsianas

  • GEF and CK contributed equally.

  • Contributors Study inception: PPS. Study design: GEF, PPS and DV. Data acquisition: GEF, CK, KF, CT, SP, IM, MP, MGT and TD. Drafting the manuscript: GEF, CK, KF, CT, SP, IM, MP, MT and TD. Revising the manuscript: PPS and DV.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.